2020 - Member of the National Academy of Sciences
2014 - Fellow of the American Academy of Arts and Sciences
2014 - Fellow, National Academy of Inventors
2009 - Member of the National Academy of Medicine (NAM)
2009 - Paul Marks Prize for Cancer Research, Memorial Sloan Kettering Cancer Center
Member of the Association of American Physicians
The scientist’s investigation covers issues in Prostate cancer, Cancer research, Cancer, TMPRSS2 and Prostate. Arul M. Chinnaiyan interconnects Fusion gene, Transcriptional Regulator ERG and Pathology in the investigation of issues within Prostate cancer. His Cancer research study incorporates themes from Bioinformatics, Molecular biology, Metastasis, Androgen receptor and ETS transcription factor family.
The various areas that Arul M. Chinnaiyan examines in his Cancer study include Immunology, Gene, Oncology and Disease. His work carried out in the field of TMPRSS2 brings together such families of science as Transmembrane Protease Serine 2, Chromoplexy, ETV1, Fluorescence in situ hybridization and TMPRSS2 Gene. The study incorporates disciplines such as PTEN, Aurora inhibitor and Cancer biomarkers in addition to Prostate.
Arul M. Chinnaiyan spends much of his time researching Prostate cancer, Cancer research, Cancer, Internal medicine and Oncology. His Prostate cancer study combines topics in areas such as TMPRSS2, Prostate and Pathology. His TMPRSS2 study integrates concerns from other disciplines, such as Transcriptional Regulator ERG, Chromoplexy and ETV1.
His study explores the link between Cancer research and topics such as Fusion gene that cross with problems in Molecular biology. His Cancer research includes themes of Computational biology, Immunology and Bioinformatics. His research in Internal medicine is mostly focused on Disease.
His primary areas of investigation include Cancer research, Prostate cancer, Cancer, Internal medicine and Oncology. Arul M. Chinnaiyan combines subjects such as Wnt signaling pathway, Carcinogenesis, KRAS, Epigenetics and Immunotherapy with his study of Cancer research. His Prostate cancer research is multidisciplinary, incorporating elements of Prostate, Metastasis and Cancer biomarkers.
He mostly deals with Breast cancer in his studies of Cancer. As part of one scientific family, Arul M. Chinnaiyan deals mainly with the area of Internal medicine, narrowing it down to issues related to the Transcriptome, and often Computational biology and Exome. Arul M. Chinnaiyan studied Oncology and Biomarker that intersect with Pathology.
His primary scientific interests are in Cancer research, Prostate cancer, Cancer, Transcriptome and Androgen receptor. His Cancer research study combines topics from a wide range of disciplines, such as Carcinogenesis, T cell, Immunotherapy, Cancer immunotherapy and Epigenetics. His study in Prostate cancer is interdisciplinary in nature, drawing from both Prostate, Metastasis and Oncology.
His Cancer research integrates issues from Exome sequencing, Exome, Clinical record, General surgery and Surgical oncology. His research integrates issues of Computational biology and DNA sequencing in his study of Transcriptome. His Androgen receptor research incorporates themes from TMPRSS2, Cell, Androgen and Regulation of gene expression.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
S.A. Tomlins;D.R. Rhodes;S. Perner;S.M. Dhanasekaran.
FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex
Marta Muzio;Arul M. Chinnaiyan;Frank C. Kischkel;Karen O'Rourke.
FADD, a novel death domain-containing protein, interacts with the death domain of fas and initiates apoptosis
Arul M. Chinnaiyan;Karen O'Rourke;Muneesh Tewari;Vishva M. Dixit.
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Daniel R. Rhodes;Jianjun Yu;K. Shanker;Nandan Deshpande.
The polycomb group protein EZH2 is involved in progression of prostate cancer
Sooryanarayana Varambally;Saravana M. Dhanasekaran;Ming Zhou;Terrence R. Barrette.
Integrative clinical genomics of advanced prostate cancer
Dan Robinson;Eliezer M. Van Allen;Eliezer M. Van Allen;Yi Mi Wu;Nikolaus Schultz.
The Receptor for the Cytotoxic Ligand TRAIL
Guohua Pan;Karen O'Rourke;Arul M. Chinnaiyan;Reiner Gentz.
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control
Bin Zhao;Xiaomu Wei;Weiquan Li;Ryan S. Udan;Ryan S. Udan.
Genes & Development (2007)
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression
Arun Sreekumar;Laila M. Poisson;Thekkelnaycke M. Rajendiran;Amjad P. Khan.
The mutational landscape of lethal castration-resistant prostate cancer
Catherine S. Grasso;Yi Mi Wu;Dan R. Robinson;Xuhong Cao.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: